Short Interest in Bionomics Limited (NASDAQ:BNOX) Increases By 1,279.0%

Posted by Clark Linder on Nov 14th, 2024

Bionomics Limited (NASDAQ:BNOX – Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 190,300 shares, a growth of 1,279.0% from the October 15th total of 13,800 shares. Based on an average daily trading volume, of 9,160,000 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Bionomics in a research note on Thursday, August 1st.

Check Out Our Latest Research Report on BNOX

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC bought a new position in Bionomics Limited (NASDAQ:BNOX – Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent reporting period. 15.90% of the stock is currently owned by institutional investors.

Bionomics Trading Down 7.6 %

Shares of NASDAQ BNOX opened at $0.29 on Thursday. Bionomics has a 1 year low of $0.18 and a 1 year high of $2.19. The company’s 50-day moving average is $0.41 and its 200 day moving average is $0.64.

About Bionomics

(Get Free Report)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.